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RESEARCH ARTICLE
Adamtsl2 deletion results in bronchial fibrillin microfibril
accumulation and bronchial epithelial dysplasia – a novel
mouse model providing insights into geleophysic dysplasia
Dirk Hubmacher1,*, Lauren W. Wang1, Robert P. Mecham2, Dieter P. Reinhardt3 and Suneel S. Apte1,*
ABSTRACT
Mutations in the secreted glycoprotein ADAMTSL2 cause recessive
geleophysic dysplasia (GD) in humans and Musladin–Lueke
syndrome (MLS) in dogs. GD is a severe, often lethal, condition
presenting with short stature, brachydactyly, stiff skin, joint contractures,
tracheal-bronchial stenosis and cardiac valve anomalies, whereas
MLS is non-lethal and characterized by short stature and severe
skin fibrosis. Although most mutations in fibrillin-1 (FBN1) cause
Marfan syndrome (MFS), a microfibril disorder leading to
transforming growth factor-β (TGFβ) dysregulation, domain-
specific FBN1 mutations result in dominant GD. ADAMTSL2 has
been previously shown to bind FBN1 and latent TGFβ-binding
protein-1 (LTBP1). Here, we investigated mice with targeted
Adamtsl2 inactivation as a new model for GD (Adamtsl2−/− mice).
An intragenic lacZ reporter in these mice showed that ADAMTSL2
was produced exclusively by bronchial smooth muscle cells during
embryonic lung development. Adamtsl2−/− mice, which died at
birth, had severe bronchial epithelial dysplasia with abnormal
glycogen-rich inclusions in bronchial epithelium resembling the
cellular anomalies described previously in GD. An increase in
microfibrils in the bronchial wall was associated with increased
FBN2 and microfibril-associated glycoprotein-1 (MAGP1) staining,
whereas LTBP1 staining was increased in bronchial epithelium.
ADAMTSL2 was shown to bind directly to FBN2 with an affinity
comparable to FBN1. The observed extracellular matrix (ECM)
alterations were associated with increased bronchial epithelial
TGFβ signaling at 17.5 days of gestation; however, treatment with
TGFβ-neutralizing antibody did not correct the epithelial dysplasia.
These investigations reveal a new function of ADAMTSL2 in
modulating microfibril formation, and a previously unsuspected
association with FBN2. Our studies suggest that the bronchial
epithelial dysplasia accompanying microfibril dysregulation in
Adamtsl2−/− mice cannot be reversed by TGFβ neutralization,
and thus might be mediated by other mechanisms.
KEY WORDS: ADAMTS-like protein, Connective tissue disorder,
Extracellular matrix, Fibrillin microfibril, Lung development
INTRODUCTION
Fibrillin (FBN) microfibrils are extracellular matrix (ECM)
structures recognizable in electron microscopy as 10- to 12-nm
fibrils, which typically form bundles. They are widely distributed
and frequently found in association with elastic fibers (Keene et al.,
1991). In the ocular zonule and dermis, microfibrils perform a
mechanical role (Pessier and Potter, 1996; Shi et al., 2013). In
several other contexts, they are recognized as playing a crucial role
in regulating the spatial distribution and activation of members of
the transforming growth factor-β (TGFβ) family by directly binding
to the large latent complexes of transforming growth factor-β
(TGFβ) or to the prodomains of bone morphogenetic proteins
(BMPs) (Sengle et al., 2008; Massam-Wu et al., 2010; Zilberberg
et al., 2012). In mice with mutant Fbn1, TGFβ dysregulation has
been identified as being a major mechanism of the observed heart,
skeletal muscle, ascending aorta and lung anomalies (Neptune et al.,
2003; Habashi et al., 2006, 2011; Cohn et al., 2007; Holm et al.,
2011). Analysis of mice with targeted inactivation of Fbn1 or Fbn2
has demonstrated that they have a crucial role in regulating both
TGFβ and BMPs (Arteaga-Solis et al., 2001; Nistala et al., 2010a,b).
Whereas humans have three fibrillins, mice have only two, with
expression of Fbn2 dominating the embryonic period. A switch in
expression from Fbn1 to Fbn2 occurs perinatally, and,
subsequently, Fbn1 expression dominates adulthood (Zhang
et al., 1994; Mariencheck et al., 1995; Corson et al., 2004).
FBN1 mutations typically cause Marfan syndrome (MFS,
incidence 2-3 in 10,000), a serious connective tissue disorder
affecting the cardiovascular and musculoskeletal systems, the eyes
and the lungs (Robinson et al., 2006). Molecular mechanisms in
MFS involve aberrant TGFβ signaling and structural anomalies, for
example defective ciliary zonules in the eye, defects of the elastic
fiber system in the aorta and altered mechanotransduction in
cardiomyocytes (Wheatley et al., 1995; Traboulsi et al., 2000;
Brooke et al., 2008; Doyle et al., 2012; Cook et al., 2014). Some
FBN1mutations cause dominant geleophysic dysplasia (GD), a rare
condition with musculoskeletal features (short stature, short digits,
and stiff joints) that are broadly the opposite of MFS (Le Goff et al.,
2011). The GD-causing mutations all localize to the TGFβ-binding
protein-like domain 5 (TB5) of FBN1 (Le Goff et al., 2011). GD is
also characterized by progressive tracheal-bronchial and cardiac
valve fibrosis, which are implicated in early lethality and whose
pathobiology is poorly understood (Le Goff and Cormier-Daire,
2009). Recessive GD is caused by mutations in ADAMTSL2 (Le
Goff et al., 2008). ADAMTSL2 encodes a secreted glycoprotein
previously shown to bind FBN1 and latent TGFβ-binding protein-1
(LTBP1) (Koo et al., 2007; Le Goff et al., 2008, 2011), suggesting
that there is a role for ADAMTSL2 in the formation and function of
microfibrils. Indeed, increased TGFβ signaling has been observed
in dermal fibroblasts derived fromGD patients (Le Goff et al., 2008,Received 29 May 2014; Accepted 5 March 2015
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2011). Using RNA in situ hybridization, it has been shown that
murine Adamtsl2 is expressed in the bronchial tree during
embryogenesis, during skeletal myogenesis and at other sites
(Koo et al., 2007).
Musladin-Lueke syndrome (MLS), a canine non-progressive,
non-lethal condition caused by a founder Arg221Cys ADAMTSL2
mutation in beagles (which is identical to a mutation identified in
GD), also causes short stature, skin and joint fibrosis with GD, but
does not give rise to cardiopulmonary problems (Bader et al., 2010;
Allali et al., 2011). Thus, musculoskeletal features and fibrosis are
common to both GD and MLS, but the severity and associated
mortality of GD appear to directly result from the lung and/or
cardiac anomalies, which are absent in MLS. MLS provides a
potential model for the pathogenesis of skeletal and skin
abnormalities in GD. However, owing to the availability of
genetic testing, the MLS mutation will likely disappear in beagle
colonies (Mellersh, 2012). In addition, logistical and economic
considerations render MLS an impractical model system for GD.
Given that MLS dogs do not develop the lung or cardiac anomalies
observed in GD, an alternative model system is required for
investigation of the pathology in these organs.
Here, we used a new mouse model of ADAMTSL2 deficiency
to understand the impact of ADAMTSL2 deletion on lung
development. This analysis also investigated the relationship
between ADAMTSL2 and microfibrils, revealing a hitherto
unsuspected impact on the FBN2 content of microfibrils.
Similarities between the Adamtsl2−/− lungs and previously
published histological findings on GD suggest that this mouse
model could be useful for further studies of GD pathogenesis and to
evaluate potential therapeutical interventions.
RESULTS
Targeted deletion of Adamtsl2 in mice leads to neonatal
lethality, profound bronchial epithelial dysplasia and cellular
glycogen accumulation
Following targeted inactivation by homologous recombination in
embryonic stem cells (Fig. 1A), intercrosses of Adamtsl2+/− mice
produced Adamtsl2−/− progeny in a Mendelian fraction (observed
27.8%; expected 25%) (supplementary material Table S1). Almost
all Adamtsl2−/− newborns were cyanotic, had gasping respiration
and died within 24 h of birth. In contrast to wild-type (WT) lungs,
those of newborn Adamtsl2−/− mice sank in fixative, indicating
poor aeration. The oropharyngeal tract of Adamtsl2−/− mice was
unaffected, their diaphragm was intact and the histology of
intercostal muscle fibers showed normal structure, including
peripheral localization of the nucleus, excluding myogenic or
other non-pulmonary causes of respiratory insufficiency (data not
shown). A few (3.1%) Adamtsl2−/− mice survived for 1-2 weeks
after birth and showed a dramatic reduction in size, along with tight
skin and limb contractures.
Quantitative real-time PCR analysis of lungs (Fig. 1B) and western
blotting with an anti-ADAMTSL2 polyclonal antibody (Fig. 1C)
showed reduced RNA and protein, respectively. The ADAMTSL2
antibody specifically detected recombinant ADAMTSL2 (Fig. 1D)
and did not cross-react with homologous thrombospondin type-1
repeats (TSRs) ofADAMTSL1 (also known as punctin-1) (Fig. 1E,F),
indicating that the antibody is unlikely to recognize tandem TSR
arrays found in other ADAMTSL proteins.
Whole-mount β-galactosidase staining of lungs, using the
intragenic lacZ reporter, showed Adamtsl2 gene expression
exclusively in the smooth muscle cell (SMC) layer of the
bronchial tree from embryonic day (E) 14.5 on to birth (Fig. 2A),
but not elsewhere within the lung, consistent with prior in situ
hybridization analysis (Koo et al., 2007). Staining intensity peaked
at E17.5 and was reduced at birth. No β-galactosidase staining was
seen in pulmonary parenchyma and vasculature of embryos.
Postnatally, Adamtsl2 expression was reduced further in bronchial
SMCs and extended into the surrounding parenchyma (data not
shown). Interestingly, in embryonic lungs from E14.5 to birth, we
observed concurrent strong expression in some bronchi, yet weak
expression in others within the same tissue sections, suggesting that
even within the bronchial tree, Adamtsl2 expression might be
extremely dynamic.
Newborn Adamtsl2−/− bronchial lumina were partially or
completely occluded by a dysplastic bronchial epithelium, and the
lumina contained vesicular material at birth (Fig. 2B, lower right).
However, no comparable anomaly of the bronchial epithelium was
obvious during embryonic development, although a few bronchi
showed altered cross-sectional profiles (Fig. 2B, left, middle). Smooth
TRANSLATIONAL IMPACT
Clinical issue
Geleophysic dysplasia (GD) is an inherited, rare and frequently lethal
condition that affects the musculoskeletal, cardiac and pulmonary
systems and the skin. Significant morbidity and mortality in GD result
from poorly understood tracheal-bronchial occlusion, which leads to
recurrent pulmonary infections and poor post-surgical recovery.
Recessive and dominant GD are caused by mutations in the secreted
extracellular matrix (ECM) proteins, ADAMTSL2 (a disintegrin and
metalloproteinase with thrombospondin motifs-like 2) and fibrillin-1
(FBN1), respectively, implying a functional link between ADAMTSL2
and fibrillin microfibrils that is not fully understood, but is thought to
involve transforming growth factor-β (TGFβ) dysregulation. ADAMTSL2
mutations in dogs cause Musladin-Lueke syndrome, whose hallmarks
are skin fibrosis and joint contractures, but these dogs do not develop
pulmonary abnormalities. In search of an alternative animal model to
analyze disease mechanisms in the lung, we investigated lung
development in ADAMTSL2-deficient (Adamtsl2−/−) mice.
Results
Adamtsl2 was expressed specifically and dynamically by embryonic
bronchial smooth muscle cells, but not by the bronchial epithelium.
Adamtsl2−/− mice died at birth due to severe bronchial epithelial
dysplasia, which occluded the bronchial lumen. This bronchial
epithelium contained glycogen-rich inclusions that were essentially
similar to cellular anomalies found in biopsies from GD-affected
individuals. Bronchial epithelial dysplasia was accompanied by a
profound increase in FBN2 of microfibrils and the amount of microfibril-
associated glycoprotein-1 (MAGP1) associated with bronchial smooth
muscle ECM. Although elevated TGFβ signaling was seen in bronchial
epithelium in late gestation, TGFβ-neutralizing antibody treatment did not
revert the epithelial dysplasia to normal. In addition, ADAMTSL2 was
shown to bind directly to FBN2 with an affinity comparable to FBN1.
Implications and future directions
This study suggests that ADAMTSL2 has amajor role in regulating FBN2
assembly in microfibrils. Thus, it could represent a crucial regulator of
microfibril composition in the bronchial smooth muscle cell layer, and
influence bronchial epithelial function through TGFβ-independent
mechanisms. The Adamtsl2−/− mouse provides a new model system
for the bronchial and cellular pathology of GD and identifies a previously
unsuspected effect of ADAMTSL2 deficiency on FBN2 microfibrils in the
embryonic period. Future studies will require the cellular mechanisms of
microfibril increase and epithelial glycogen accumulation in mutant
bronchi to be addressed. Because the globalAdamtsl2 inactivation leads
to neonatal death, tissue specific conditional deletion will be required to
determine postnatal effects of ADAMTSL2 deficiency on limbs, heart
valves and skin.
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muscle actin staining at P0 showed an intact, apparently unaltered,
SMC layer and bronchial epithelial cells were all positive for
cytokeratin, i.e. they retained epithelial differentiation (supplementary
material Fig. S1A,B).Col IV staining indicated an intact and apparently
normal bronchial epithelial basement membrane at birth
(supplementary material Fig. S1F). Staining for markers of epithelial
differentiation, PKCζ and ZO-2 indicated their presence in the
epithelium as expected, but at reduced levels and with considerable
spatial disorganization (supplementary material Fig. S1G,H,I). There
was no significant alteration of cell proliferation or apoptosis within the
bronchial wall (supplementary material Fig. S2).
Newborn Adamtsl2−/− bronchial epithelial cells were
disorganized, with enlarged abnormal vesicles continuous with
the epithelial apical surface (Fig. 3A). Both the intra-lumenal and
epithelial vesicles stained strongly with periodic acid Schiff (PAS)
stain (Fig. 3B), consistent with the previously documented
appearance of GD tracheal, liver and cardiac biopsies, which had
shown carbohydrate-enriched inclusions in these organs, and led to
designation of GD as a glycoprotein storage disorder (Spranger
et al., 1984; Shohat et al., 1990; Santolaya et al., 1997). We found
that this PAS-positive material was sensitive to α-amylase
digestion, indicative of substantial glycogen content (Fig. 3C).
The vesicles stained positive for the endoplasmic reticulum (ER)
marker KDEL, but did not stain with the lysosomal marker Lamp-2
or the Golgi marker GM-130 (supplementary material Fig. S1C-E),
suggesting glycogen accumulation in the secretory pathway.
Staining with Toluidine Blue did not result in metachromasia;
Alcian Blue staining at acidic pH and biotinylation did not strongly
label the vesicles, indicative of a lack of substantial proteoglycan,
acid mucin or protein content, respectively (data not shown). Thus,
although overall bronchial architecture was preserved, Adamtsl2−/−
newborn mice had severe bronchial epithelial dysplasia.
Electron microscopy of newborn lungs showed that Adamtsl2−/−
bronchial epithelial cells were engorged with membrane-bound
vesicles containing a granular material similar to that found in the
luminal vesicles (Fig. 4A,B). The intracellular vesicles were
Fig. 1. Adamtsl2 targeting strategy and validation of inactivation. (A) Cartoon of the gene-targeting construct (top) and following Zp3-Cre excision of the
neomycin (neo) cassette (bottom), which was performed to improve β-galactosidase staining. Primers used for genotyping (top) and for qRT-PCR (bottom) are
indicated as arrows. (B) Adamtsl2 qRT-PCR was performed to verify Adamtsl2 deletion (means±s.d., n=3 per genotype) using two primer pairs with
RNA extracted from lung tissue prior to Zp3-Cre mediated neo excision. Note that the expression of the RNA upstream of the targeting site (exon 2-3) is reduced,
presumably due to the presence of the neo cassette, whereas downstream primers (exon 8-9) produce no product in Adamtsl2−/− lung. (C) Western blot of total
lung protein from newborn mice probed with polyclonal antibody against the C-terminus of ADAMTSL2 (C3). 200 µg of total protein was loaded per lane. Two
ADAMTSL2 bands (attributed to N-glycosylated and unmodified forms) at ∼150 kDa (arrows) are absent in protein extracts from Adamtsl2−/− lungs and are
present at reduced levels in Adamtsl2+/− lungs (n=3 for WT and Adamtsl2−/−; n=2 for Adamtsl2+/−). (D) Conditioned medium from HEK293 cells secreting
recombinant human ADAMTSL2 was used to confirm the reactivity and specificity of the anti-ADAMTSL2-C3 antibody. No reactivity was seen in the medium of
empty-vector-transfected cells. (E) Cartoon of the domain organization of ADAMTSL1 (punctin-1) and ADAMTSL2. The localization of the
anti-ADAMTSL2 C3 antibody epitope is indicated. (F) Western blot analysis of equal amounts of ADAMTSL1 (L1) and ADAMTSL2 (L2) detected with the anti-
ADAMTSL2 antibody (L2C3, left-hand panel) or the anti-Myc (α-Myc) antibody (right-hand panel). Note that the anti-ADAMTSL2 antibody specifically recognized
ADAMTSL2, whereas the α-Myc antibody recognized both proteins. The band at ∼50 kDa in the ADAMTSL2 lanes represents an ADAMTSL2 degradation
product. En2SA, En2 splice acceptor; IRES, internal ribosome entry site; ns, non-specific bands.
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typically located apically, but were also found in some cells between
the basement membrane and the nucleus (Fig. 4E). The vesicles
contained a fine, granular, electron-dense material (Fig. 4F), with a
similar appearance to that previously reported in GD biopsies of
liver, skin, cartilage, and the heart valve (Spranger et al., 1984;
Shohat et al., 1990; Pontz et al., 1996), but contained no intact
organelles or visible chromatin. No consistent differences were
detected in the morphology of the bronchial SMC layer (Fig. 4G,H).
Thus, lack of ADAMTSL2 produced by bronchial SMCs led to a
profound dysplasia of the bronchial epithelium at birth, but without
apparently altering the bronchial SMC layer or overall lung
morphology during the embryonic period.
Dysregulation of ECM in the bronchial microenvironment
characterizes Adamtsl2−/− bronchi
The embryonic period is characterized by the expression of Fbn2
rather than Fbn1 mRNA (Mariencheck et al., 1995; Zhang et al.,
1995). To determine whether ADAMTSL2 acted locally at the
interface between the bronchial epithelium and the SMCs, we
compared FBN2 and FBN1 staining around Adamtsl2−/− and WT
bronchi as well as in the adjacent vasculature, which does not
express FBN2 or ADAMTSL2. We consistently found stronger
FBN2 immunostaining in the bronchial SMC layer of Adamtsl2−/−
lungs at birth (P0) compared to WT (Fig. 5A,B). In contrast, FBN2
staining was unaltered in Adamtsl2−/− bronchial arteries and in
other tissues, where Adamtsl2 is not expressed (Fig. 5A, asterisk;
data not shown), suggesting that ADAMTSL2 acted locally in the
bronchial ECM. Consistent with lower Fbn1 mRNA expression
until late gestation and postnatally, immunostaining showed weak
FBN1 immunostaining at E14.5 around blood vessels in both
Adamtsl2−/− and WT mice (supplementary material Fig. S3). At
E17.5 and at birth, staining for FBN1microfibrils was strong around
blood vessels, consistent with the localization of Fbn1 gene
expression, and did not differ between Adamtsl2−/− and WT mice.
At birth, FBN1 immunostaining seemed to be slightly enhanced or
better defined at the interface between the bronchial epithelial and
the SMCs in Adamtsl2−/− bronchi. However, quantification of the
FBN1 immunofluorescence signal did not result in statistically
significant differences. The antibody-independent histochemical
oxytalan stain to visualize all microfibrils regardless of fibrillin
Fig. 2. Expression of Adamtsl2 in
lung and profound bronchial
epithelial dysplasia in Adamtsl2−/−
mice. (A) The top panels show
representative β-galactosidase
staining of whole lungs at embryonic
day E14.5 (from n=3), E17.5 (from
n=6) and postnatal day P0 (from n=3)
(circle at E14.5 outlines the lung, with
the heart still attached; arrows indicate
stained bronchi; inset shows no
β-galactosidase staining in WT tissue
at E17.5). The lower panels show a
β-galactosidase-stained section at
E14.5 indicating emerging Adamtsl2
expression in some bronchi (arrows),
and eosin- and β-galactosidase-
stained sections of lung tissue (center
and right-hand panels) with strong
expression of Adamtsl2 around
bronchi at E17.5 and reduced staining
at P0. Scale bars: 50 µm.
(B) Representative H&E staining of
WT and Adamtsl2−/− lung sections at
E14.5 (from n>3), E18.5 (from n>5)
and P0 (from n>6). Arrows show
occluded bronchi at P0. Adamtsl2−/−
lungs at E14.5 and E18.5 showed
minimal to no difference in bronchial
development. Scale bars: 25 µm.
B, bronchi; BV, blood vessel.
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isoform composition (Inoue et al., 2012), showed consistently
greater abundance of oxytalan fibers inAdamtsl2−/− bronchi (Fig. 5C).
In transmission electronmicroscopy (TEM) images, the microfibrils
appeared to be structurally normal and we were not able to detect
quantitative changes in microfibrils or other structural ECM
components (Fig. 4I,J). This could be caused by the much higher
magnification used to visualize microfibrils in TEM. Taken
together, we concluded that the absence of ADAMTSL2 results in
the persistence of fibrillin microfibrils in the bronchial wall at birth,
but not in the adjacent vasculature, and that these microfibrils have a
higher amount of FBN2 than WT bronchi.
To further resolve the spatial relationship between FBN1 and
FBN2microfibrils in the bronchial wall, we co-stained lung sections
with antibodies against FBN1 and FBN2 that were directly labeled
with fluorophores. As shown above, in newborn Adamtsl2−/−mice,
FBN2 staining was especially strong at the interface between
the bronchial epithelium and SMCs, i.e. below the bronchial
epithelium basement membrane, where it partially colocalized
with FBN1 (Fig. 5D, center and right-hand panels). By using
non-radioactive in-situ hybridization (ISH) for improved cellular
resolution compared to the previously reported radioactive ISH
(Mariencheck et al., 1995; Zhang et al., 1995), we found that Fbn2
mRNA was localized to the bronchial epithelium of embryonic
lungs, but was not detected in blood vessels (Fig. 5E). At E16.5,
Fbn2mRNAwas expressed at very low levels in the bronchial SMC
layer as compared with the bronchial epithelium. However,
bronchial SMC became the exclusive site of Fbn2 expression at
birth, although at much lower levels than observed in the embryonic
bronchial epithelium prior to birth. Fbn1 mRNA was strongly
expressed in the blood vessels during embryonic development, but
was detected only at low levels in the bronchial SMCs (Fig. 5E). The
intensity of Fbn1 or Fbn2 mRNA expression observed by ISH was
not different in Adamtsl2−/− and WT lungs. We observed no
changes in quantitative mRNA expression levels for Fbn1 or
Fbn2 (Fig. 5F), suggesting that the observed staining differences
between Adamtsl2−/− andWT lungs results from post-transcriptional
mechanisms, e.g. enhanced FBN2 assembly, altered intermolecular
interactions, or reduced microfibril degradation or turnover.
Staining for microfibril associated glycoprotein-1 (MAGP1),
which localizes to microfibrils and binds to FBN1 and FBN2
in vitro (Segade et al., 2000, 2002), was strongly enhanced in
bronchial SMC ECM of Adamtsl2−/− mice at birth (Fig. 6A, left).
Because ADAMTSL2, FBN1 and FBN2 interact with LTBP1 in vitro
(Isogai et al., 2003; Le Goff et al., 2008), we compared the
localization of LTBP1 in Adamtsl2−/− and WT bronchi (Fig. 6A,
middle). LTBP1 immunostaining was consistently stronger in
Adamtsl2−/− bronchial epithelium compared to the WT. However,
in contrast to increased FBN2 and MAGP1 in Adamtsl2−/− bronchi,
LTBP1 was not localized to bronchial SMCs. Because fibronectin
(FN) forms an ECM network necessary for the subsequent
deposition of fibrillin microfibrils and LTBPs (Taipale et al.,
1996; Kinsey et al., 2008; Sabatier et al., 2009; Zilberberg et al.,
2012), we analyzed bronchial FN distribution in Adamtsl2−/− and
WT lungs (Fig. 6A, right). FN staining was comparable or slightly
reduced in Adamtsl2−/− lungs and its overall distribution was
unaltered. Quantification showed a statistically significant
increase in MAGP1 and LTBP1 in Adamtsl2−/− lungs, whereas
the levels of FN were unchanged (Fig. 6B). Therefore, the
accumulation of FBN2 microfibrils cannot be explained by an
augmentation of the FN scaffold. Gene expression levels of these
ECM molecules in Adamtsl2−/− and WT lung were comparable at
birth (Fig. 5F).
ADAMTSL2 directly binds to FBN2
Because ADAMTSL2 is not a protease, nor is known to be
functionally associated with proteases and therefore does not
Fig. 3. Glycogen accumulation in the bronchial
epithelium of Adamtsl2−/− mice. (A) Toluidine
Blue staining of 1-µm-thick epoxy-embedded
sections of lung tissue. The basement membrane
is outlined by a red dashed line. Some vesicles
occluding the lumen are stained strongly with
Toluidine Blue (white arrows), whereas others,
more centrally located, appeared unstained (black
arrow). Vesicles attached to epithelial cells are
marked with red arrows (from n=2 per genotype).
(B,C) Vesicles in Adamtsl2−/− mice contain
glycogen as shown by periodic acid Schiff staining
(B, PAS) which is sensitive to amylase digestion
(C, right-hand panel). Note that the basement
membrane PAS staining is amylase resistant
(C, right-hand panel, white arrows). Some
glycogen is contained within large structures
(B, right-hand panel, white arrows), whereas some
is found in smaller globules (B, right-hand panel,
black arrows) (from n=4 per genotype).
B, bronchus.
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directly degrade FBN2, we asked whether it could bind to FBN2 as
away of influencing its assembly. ADAMTSL2 has previously been
shown to interact with the N-terminal half of FBN1 (Le Goff et al.,
2011). We used surface plasmon resonance technology to analyze
the binding of recombinant ADAMTSL2 to recombinant halves of
FBN2 and FBN1 (as a control) (Fig. 7A,B). We found that, in
addition to binding to both halves of FBN1, ADAMTSL2 also
bound to the N- and C-terminal halves of FBN2 with affinities that
were comparable to those for FBN1 binding (Fig. 7C). Strongest
binding of ADAMTSL2 was observed for the C-terminus of FBN1
(KD=8.0 nM) and weakest binding for the C-terminus of FBN2
(KD=35.2 nM). Interestingly, the N-terminal fragments of FBN1
and FBN2 showed very similar KD values for their interaction with
ADAMTSL2 (14.3 nM and 16.3 nM, respectively). These results
indicate that there are at least two distinct high-affinity binding sites
for ADAMTSL2 on both FBN1 and FBN2.
Alterations in canonical TGFβ signaling precede bronchial
epithelial dysplasia
Because of the observed changes in microfibril composition in
Adamtsl2−/− bronchi, and because fibrillins regulate and integrate
TGFβ and BMP signaling (Neptune et al., 2003; Le Goff et al.,
Fig. 4. Ultrastructure of the bronchial wall of Adamtsl2−/− mice. (A-F) Ultrastructural analysis of the newborn bronchial wall using TEM. In contrast to
WT bronchial epithelium (A,C), the bronchial epithelium in Adamtsl2−/− (−/−) mice is disorganized (B,D,E) and membrane-bound vesicles engorged with
granular, electron dense material fill mutant cells and the lumen (E,F). (G-H) The SMC layer of the bronchial wall did not show consistent differences
between WT and Adamtsl2−/− mice. (I-J) Higher magnification of the ECM around the bronchial SMCs (from n=4 per genotype). B, Bronchi; Col, collagen
fibers; EF, elastic fiber; EP, bronchial epithelium; MF, microfibril.
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Fig. 5. Peribronchial microfibril dysregulation in Adamtsl2−/− lungs. (A) Immunolocalization of FBN2 (green) in frozen (E16.5) (from n=3 per genotype)
or paraffin-embedded (E17.5, P0) (from n>6 per genotype) lung sections. Note the stronger FBN2 staining in Adamtsl2−/− bronchi compared to the WT.
The genotype of the E16.5 controls is Adamtsl2+/−. (B) Quantification of mean±s.d. integrated density of the fluorescence signal for FBN2 at E16.5 (n=3 per
genotype), E17.5 (n=3 per genotype) and P0 (n>6 per genotype). A small, but statistically significant difference between the WT and Adamtsl2−/− lungs
was observed at E16.5. A strong increase in the mean integrated density was observed in the Adamtsl2−/− lungs at P0. (C) The total amount of microfibrils is
greater in the bronchial wall of newborn Adamtsl2−/− lungs as assessed by histochemical staining for oxytalan fibers (arrows) (from n=4 per genotype).
(D) Co-immunostaining of FBN2 (green) and FBN1 (red) in frozen sections from lung tissue at birth using antibodies covalently labeled with the respective
fluorophores. Nuclei are counterstainedwith DAPI (blue). In theAdamtsl2−/− bronchi, FBN2 staining predominates peri-bronchially, but is absent in blood vessels.
In WT and mutant mice, FBN1 staining is present primarily in blood vessels (white asterisk), with weaker staining of the bronchial wall. The lower panel shows a
magnified view of sub-epithelial FBN2 accumulation (green) in an Adamtsl2−/− bronchus (from n=2 per genotype). (E) In-situ hybridization for Fbn2 and
Fbn1mRNA (red) shows that there is strong Fbn2 expression in bronchial epithelium at E16.5 in WT and Adamtsl2−/−mice (asterisks) (from n>4 per genotype).
Note the absence of Fbn2 expression in more developed bronchi (upper left panel) and weak Fbn2 expression in the bronchial smooth muscle cell layer (arrows).
Fbn1 is predominantly expressed in the pulmonary blood vessels. (F) qRT-PCR analysis of expression of microfibril associated genes in lung at P0 normalized to
expression of Gapdh (mean±s.d., n=3 per genotype). No significant changes were detected between Adamtsl2−/− (−/−) and WT lungs. Scale bars: 25 µm.
B, bronchi; asterisk, blood vessel.
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2008; Sengle et al., 2008; Nistala et al., 2010b; Holm et al., 2011),
we analyzed the respective signaling pathways (Fig. 8;
supplementary material Fig. S4). Smad2 phosphorylation was
increased in Adamtsl2−/− lung extracts at E17.5, but not at birth
(Fig. 8A), with strong nuclear staining for phosphorylated SMAD2
(pSmad2) in bronchial epithelial cells of E17.5 Adamtsl2−/− mice
(Fig. 8B), indicative of enhanced canonical TGFβ signaling. There
were no consistent staining differences for pSmad2 in WT versus
Adamtsl2−/− SMCs or parenchyma (Fig. 8B, compare left and
middle panel). BMP signaling (as assessed by measuring the
phosphorylation of Smad1/5/8) (Fig. 8A) and non-canonical TGFβ
signaling pathways (as assessed by measuring phosphorylation of
Erk1/2 or p38) were comparable in WT and Adamtsl2−/− lungs
(supplementary material Fig. S4A). We injected TGFβ-neutralizing
antibody (NAB) at 13.5 and 17.5 days of gestation into pregnant
Adamtsl2+/− dams crossedwithAdamtsl2+/−males, and analyzed the
lungs of newborn mice (Fig. 8C). Although absence of nuclear
pSmad2 staining in both wild-type and null lungs showed the
effectiveness of the treatment with TGFβ neutralizing antibody
(supplementary material Fig. S4B), this treatment did not rescue
bronchial epithelial dysplasia in Adamtsl2−/− lungs when compared
with the IgG control (Fig. 8C).
DISCUSSION
We have discovered that, in contrast to GD andMLS, the absence of
ADAMTSL2 in mice manifests as neonatal death, probably
resulting from bronchial occlusion. This finding is relevant to GD
given that narrowing of the trachea and major bronchi, as well as
recurrent respiratory infections, are observed in children with GD
(Shohat et al., 1990; Panagopoulos et al., 2005; Giray et al., 2008).
To be detrimental, bronchial narrowing would not need to involve
the entire length of the airways because local occlusion of proximal
airways would result in the lack of aeration distally. Indeed,
Adamtsl2 expression in bronchi is dynamic, and the observed
bronchial abnormalities were not equally severe in all bronchi. A
small ventricular septal defect was also present in these mice and
will be described elsewhere.
Previous ultrastructural analysis of GD liver, cartilage and skin
biopsies has identified large membrane-bound cellular vesicles
containing a fine granular material (Spranger et al., 1984; Shohat
et al., 1990; Santolaya et al., 1997). However, the identity of the
material was not known. Here, in Adamtsl2−/− bronchi, we
unequivocally identified this material as glycogen for the first time,
but the mechanism underlying its accumulation remains unclear.
Although we observed bronchial epithelial TGFβ dysregulation at
E17.5, this did not persist to birth, and treatment with TGFβ-
neutralizing antibody during mid-to-late gestation did not remedy
bronchial epithelial dysplasia or glycogen accumulation in
Adamtsl2−/− lungs.
Analysis of bronchial ECM provided additional new and
unexpected observations. We observed that Adamtsl2−/− bronchi at
birth had more microfibrils, consisting mainly of FBN2, as well as
increased associatedMAGP1, whereas the morphology of SMCs, the
cells that express Adamtsl2 mRNA, was unaltered as assessed by
light microscopy and TEM. FBN2 constitutes the major fibrillin
isoform during the embryonic period. As shown here and reported
previously, FBN2 is expressed and secreted by bronchial epithelial
cells but is present only around bronchial SMCs, as shown by
Fig. 6. Altered distribution of microfibril-
associated ECMproteins inAdamtsl2−/− lungs.
(A) Immunolocalization of the microfibril-
associated proteins MAGP1, LTBP1 and
fibronectin (FN) in frozen lung sections at P0. Note
stronger MAGP1 and LTBP1 staining in bronchi
and parenchyma or bronchial epithelium,
respectively, in Adamtsl2−/− lung (from n=4)
compared to the WT (from n=3). Fibronectin
appeared to be slightly reduced in Adamtsl2−/−
lungs compared to the WT. FN did not localize to
the bronchial epithelium. (B) Quantification of
mean±s.d. integrated density of fluorescence
signals for the respective antibodies. A statistically
significant increase in intensity was observed for
MAGP1 and LTBP1 in Adamtsl2−/− (n=4) lungs
compared to the WT (n=3). Scale bars: 25 µm.
B, bronchi; asterisk, blood vessel.
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immunofluorescence microscopy (Zhang et al., 1995). The switch
from FBN2 as the prevalent isoform, to FBN1 occurs around birth,
when Fbn2 transcription decreases while Fbn1 mRNA is increased
(Mariencheck et al., 1995; Zhang et al., 1995). Analysis of microfibril
assembly in cultured fibroblasts has shown that in the presence of
FBN1 and FBN2, both are assembled into microfibrils without
apparent bias for either isoform (Beene et al., 2013). Enhancement of
FBN1 assembly and/or binding to recombinant fibrillin fragments has
been shown for other members of the ADAMTS family, including
ADAMTS10, ADAMTSL4 and ADAMTSL6 (Kutz et al., 2011;
Saito et al., 2011; Gabriel et al., 2012). Given that FBN2 accumulates
around bronchial SMCs in the absence of ADAMTSL2, it is possible
that ADAMTSL2 regulates FBN2 assimilation into microfibrils
during the embryonic period, such as by modulating the avidity for
FBN2 binding to FN or FBN2 self-assembly. Previous studies have
identified FN and heparan-sulfate-containing proteoglycans as
requirements for microfibril assembly because their absence
abolishes the formation of microfibrils (Tiedemann et al., 2001;
Kinsey et al., 2008; Sabatier et al., 2009; Baldwin et al., 2014).
ADAMTSL2 offers a potentially new mechanism that acts locally to
selectively restrict FBN2 incorporation into microfibrils in a tissue-
specific manner. ADAMTSL2 bound to FBN1 and FBN2 with
similar affinities, and it is possible that ADAMTSL2 could similarly
control FBN1assembly intomicrofibrils.However, owing to perinatal
lethality, a similar effect on FBN1 could not be addressed in this
mouse model. Moreover, Adamtsl2 expression seemed to be
downregulated in the bronchi after E17.5, suggesting it could be a
mechanism restricted to the embryonic period. Alternatively,
ADAMTSL2 could perform isoform-specific functions, for which
one would predict isoform-specific binding sites for ADAMTSL2 on
FBN1 or FBN2. In this regard, future studies are required to map the
binding sites of FBN1 and FBN2 on ADAMTSL2.
The finding that ADAMTSL2 is expressed in bronchial SMCs
and that microfibrils formed subjacent to the bronchial basement
membrane influence the integrity of bronchial epithelial cells,
suggests that the cells might respond specifically to the composition
and/or quantity of microfibrils. FBN2 microfibrils are structurally
different from FBN1microfibrils (Carta et al., 2006). FBN2 harbors
two RGD sites (one RGD site in FBN1) and contains a distinctive
glycine-rich domain (whereas there is a proline-rich domain in
FBN1) (Piha-Gossack et al., 2012). The RGD sites on FBN1 and
FBN2 differentially influence cell behavior of pulmonary
fibroblasts (Sakamoto et al., 1996; McGowan et al., 2008).
However, a direct effect on epithelial cells is unlikely, because a
basement membrane separates bronchial epithelial cells from
bronchial SMC. Alternatively, the observed phenotypic changes
in the bronchial epithelium could be caused by microfibril-
associated proteins, including growth factors, whose localization
and quantity in the cellular microenvironment would depend on the
specific subtype of microfibrils formed. For example, in the tight
Fig. 7. ADAMTSL2 binds to FBN1 and
FBN2. (A) Domain structure of human
FBN1 and FBN2. The peptides used in the
binding assays with ADAMTSL2 are
marked with brackets. (B) ADAMTSL2 (left,
preparation A and B) and fibrillin peptides
(right) were separated on 7.5%
polyacrylamide gels under reducing
conditions followed by Coomassie staining
to demonstrate the purity of protein
preparations. (C) Binding of immobilized
ADAMTSL2 to soluble N- or C-terminal
fragments of FBN1 or FBN2, respectively,
was measured by surface plasmon
resonance (Biacore) (n=2). The KD for
FBN1-N was similar to that previously
published for a slightly different N-terminal
fragment (60 nM) (Le Goff et al., 2011).
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skin mouse, mutant FBN1 microfibrils enhance MAGP2 and
collagen I deposition in the skin (Lemaire et al., 2004). FBN2
directly interacts with MAGP1 and MAGP2, and MAGP1 inhibits
LTBP1 binding to fibrillin microfibrils, resulting in elevated TGFβ
signaling (Penner et al., 2002; Werneck et al., 2004; Massam-Wu
et al., 2010). We showed an increase of LTBP1 deposition in
bronchial epithelial cells, concomitant with an excess of FBN2
microfibrils and MAGP1 in mutant bronchial SMC. Finally, the
dysregulation of soluble growth factors tethered to these ECM
complexes could be responsible for the alterations in the bronchial
epithelium. Although we observed TGFβ dysregulation in
Adamtsl2−/− bronchial epithelium during late development, it was
normal at birth and TGFβ-neutralizing antibody treatment did not
reverse the abnormal bronchial epithelial morphology or glycogen
accumulation. The neutralizing antibody used in this study has
previously been shown to efficiently reduce TGFβ signaling during
embryonic development when employed at a similar dose range that
used here (Neptune et al., 2003; Nakanishi et al., 2007). Therefore,
we conclude that a different mechanism, not involving TGFβ must
be invoked to explain the bronchial epithelial anomaly.
That mutations in ADAMTSL2 cause different phenotypes in
humans, dogs and mice suggests potential modifier genes in the
respective species. GD and MLS share stiff or tight skin, joint
contractures and short stature. GD and the novel mouse model of
ADAMTSL2 deficiency presented here, share pulmonary and
cardiac involvement with GD. The ventricular septal defect is a
unique feature of the mouse model that is not commonly seen in
GD, which usually results in postnatal aortic valve thickening.
However, the bronchial epithelial dysplasia seen in Adamtsl2−/−
mice authentically replicates a specific effect of Adamtsl2
deficiency on target cells, which we have characterized here in
detail, identifying glycogen as a major component of the enlarged
vesicles.
In summary, the present work provides a new mouse model
of GD and identifies a previously unsuspected binding of
ADAMTSL2 to FBN2, and effect on FBN2 assembly. We further
Fig. 8. Enhanced canonical TGFβ signaling in
Adamtsl2−/− bronchial epithelium. (A) Western
blots for pSmad2 (canonical TGFβ signaling) or
pSmad1/5/8 (BMP signaling) and total Smad2/3
or Smad1, respectively, from lung protein extracts
at E17.5 (left) and P0 (right) are shown (n=1 for
WT, n=4 for Adamtsl2−/−; n=4 for Adamtsl2+/−)
and P0 (right, n=3 for WT and Adamtsl2−/−; n=2
for Adamtsl2+/−). Equal amounts of protein were
loaded and the mean±s.d. intensity per pSmad
band was quantified using ImageJ and
normalized to the intensity of the band for the
respective total Smad (A, bottom) (n=3 for WT
and Adamtsl2−/−; n=2 for Adamtsl2+/−).
(B) pSmad2 immunohistochemistry shows strong
nuclear staining in Adamtsl2−/− bronchial
epithelium (β-galactosidase staining for Adamtsl2
expression in blue is in SMCs) at E17.5 compared
to the WT (from n=3 per genotype). In the control
section, the primary anti-pSmad2 antibody (AB)
was omitted. (C) Experimental scheme for
administration of pan-TGFβ neutralizing antibody
(NAB) 1D11 and control IgG injection (top). H&E
staining shows occluded bronchi in NAB-treated
lungs from Adamtsl2−/− mice (from n=7), but not
from WT (from n=6). Adamtsl2−/− (n=6) and WT
(n=2) mice were analyzed from the IgG-injected
control group. Scale bars: 25 µm, if not indicated
otherwise.
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demonstrate that the bronchial occlusion is not a consequence of
TGFβ dysregulation. Future studies will address the mechanisms by
which ADAMTSL2 regulates FBN2 microfibrils. Although global
Adamtsl2 inactivation leads to neonatal death, tissue specific
conditional deletion, for which this Adamtsl2−/− allele can be
used, could provide insights on effects of ADAMTSL2 deficiency
in the limbs and skin.
MATERIALS AND METHODS
Transgenic mice
C57BL/6Nmicewith a targeted deletion ofAdamtsl2were obtained from the
KOMP initiative (NIH, Bethesda, MD). They were crossed to C57BL/6J-
TgN (Zp3-Cre)93Knwmice (Jackson Laboratory, Bar Harbor, ME) to delete
the Neo cassette (Fig. 1A). Neo-deleted mice were subsequently used for β-
galactosidase staining, thus utilizing intragenic lacZ as a surrogate for
Adamtsl2 mRNA expression. All mice were maintained in the C57BL/6N
genetic background at the Biological Resources Unit of the Cleveland Clinic
under protocols approved by the Institutional Animal Care and Use
Committee (protocol numbers 2011-0557 and 2012-0818) with a 12-h-
light–12-h-dark cycle, controlled temperature and food and water ad libitum.
Genotyping and tissue harvesting
Genomic DNA isolated from tail biopsies was used for genotyping by PCR
with specific forward and reverse primers (supplementarymaterial Table S2).
Primers were purchased from Integrated DNA Technology (Coralville, IA).
Adamtsl2−/−mice andwild-type littermates (used as controls in all aspects of
this work) were obtained from Adamtsl2+/− intercrosses. Mouse tissues were
obtained after euthanasia was performed as recommended by the American
Veterinary Medical Association Panel on Euthanasia.
β-Galactosidase staining
Tissue was fixed in 4% paraformaldehyde (Electron Microscopy Sciences,
Hatfield, PA) overnight and stained with potassium ferrocyanide, potassium
ferricyanide and 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal)
(Denville Scientific, South Plainfield, NJ) as described previously
(McCulloch et al., 2009).
Histology and immunostaining
Tissue was fixed in 4% paraformaldehyde in phosphate-buffered saline
(PBS, pH 7.2). Paraffin sections were used for hematoxylin & eosin,
periodic-acid Schiff (PAS) and Masson trichrome staining according to
standard procedures. PAS staining was performed with or without
pretreatment with human amylase from saliva for 30 min at room
temperature. Elastic fibers were visualized using the Hart’s stain. The
antibodies and antigen retrieval steps used for immunofluorescence and
immunohistochemistry are summarized in supplementary material
Table S3. The polyclonal fibrillin-1 (anti-rF6H), fibrillin-2, MAGP1 and
LTBP1-K antibodies were as described previously (Tiedemann et al., 2001;
Trask et al., 2001; Chen et al., 2007; Weinbaum et al., 2008). Fluorophore-
conjugated secondary antibodies were purchased from Life Technologies
(Grand Island, NY). TUNEL staining for apoptotic cells was performed
using the DeadEnd Fluorometric TUNEL System (Promega, Madison, WI)
following the manufacturer’s instructions. To quantify the fluorescence
signal, the mean intensity of the respective single channel from 2-4 frames of
three biological replicates was measured using ImageJ (NIH) and mean
value and standard deviation were calculated using the Origin software
package (Originlab). Experimental and control groups were compared using
the two-tailed Student’s t-test and P<0.05 was considered statistically
significant.
Staining for oxytalan fibers
De-paraffinized sections were incubated for 30 min in 10% Oxone (catalog
number 208036, Sigma, St Louis, MO), rinsed with water and 70% ethanol,
stained for 1 h in aldehyde-fuchsin (pH 1) (#26328-01, Electron
Microscopy Sciences, Hatfield, PA), rinsed in 95% ethanol and
counterstained with eosin (Inoue et al., 2012).
Biotinylation of tissue sections
To biotinylate lung tissue, sections were incubated for 2 min in PBS (pH
8.0) followed by 30 min with 10 mM Sulfo-NHS-LC-Biotin (Thermo
Fisher Scientific, Waltham, MA) in PBS (pH 8.0). Sections were washed
twice in distilled water and once with 0.1 M sodium carbonate.
Subsequently, sections were blocked with 5% normal goat serum in PBS
(pH 7.2) for 30 min at room temperature and incubated with a streptavidin–
rhodamine conjugate (Jackson ImmunoResearch Laboratories, West Grove,
PA) (1:200 in blocking buffer) for 1 h at room temperature. After washing,
slides were mounted with ProLong Gold/DAPI (Life Technologies, Grand
Island, NY).
Electron microscopy
Lungs were fixed with 2.5% glutaraldehyde with 4% paraformaldehyde in
0.2 M sodium cacodylate buffer, pH 7.4, and embedded in epoxy resin. Thin
sections (85 nm) were stained with osmium tetroxide and viewed with a
Phillips CM12/STEM transmission electron microscope (FEI Company,
Delmont, PA) equipped with a digital 11-megapixel CCD camera (Gatan,
Pleasanton, CA).
Quantitative real-time PCR
Total RNA was extracted from freshly dissected lung tissue using TRIzol
Reagent (Life Technologies, Grand Island, NY), according to the
manufacturer’s protocol. The concentration and purity of the RNA was
determined with the Nanodrop ND-1000 spectrophotometer (Thermo
Fisher Scientific, Waltham, MA). Reverse transcription of 1 µg total RNA
was performed using the High Capacity cDNA Reverse Transcription Kit
(Life Technologies, Grand Island, NY). Quantitative real-time PCR (qRT-
PCR) was performed in triplicates in 384-well hard-shell PCR plates (Bio-
Rad, Hercules, CA) using 0.125 µl cDNA and SybrGreen master mix (Life
Technologies, Grand Island, NY) in a total volume of 10 µl in a CFX384
Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA). Primers
were designed using the PrimerQuest Design Tool (Integrated DNA
Technologies, Coralville, IA) and purchased from the same supplier. The
sequences of the primers are listed in supplementary material Table S2. PCR
conditions were: (1) 50°C, 2 min; (2) 95°C, 10 min; (3) 95°C, 15 s; (4) 60°
C, 1 min, (5) repeat step 3 and 4 for 39 cycles. ΔCT values were normalized
to those for Gapdh or Hprt1.
In-situ hybridization
Sections (6-µm thick) were de-paraffinized and hybridized with a specific
probe for mouse Fbn2 or Fbn1 mRNA (Advanced Cell Diagnostics,
Hayward, CA). Hybridization and detection was performed using the
RNAScope 2.0 HD Red detection kit and HybEZ™ oven (Advanced Cell
Diagnostics, Hayward, CA) according to the manufacturer’s instructions.
Western blotting and blot quantification
Lung protein extracts were prepared by homogenizing lung tissue (Ultra-
Turrax T25) in 20 ml/g (v/w) T-PER Reagent (Thermo Fisher Scientific,
Waltham, MA) including protease inhibitor (Complete Mini EDTA-free,
Roche, Indianapolis, IN) and phosphatase inhibitor (PhosStop, Roche,
Indianapolis, IN). After homogenization, samples were ultrasonicated
(QSonic) and cleared (20,000 g, 5-10 min, 4°C). 100–200 µg of protein per
lane were separated under reducing conditions by SDS-PAGE, and western
blotting was performed as described previously (Kutz et al., 2011). Cloning
and purification of ADAMTSL1 (punctin-1) and ADAMTSL2 were as
described previously (Hirohata et al., 2002; Koo et al., 2007). Primary
antibodies are listed in supplementary material Table S3. For quantification,
blots were scanned, the integral density of specific bands was measured
using ImageJ, and the ratio of phosphorylated to total protein was used for
statistical analysis using the two-tailed Student’s t-test (OriginLab
software).
Intermolecular interaction analysis by surface plasmon
resonance
Purified fibrillin peptides and ADAMTSL2 were diluted in 10 mM MES
buffer, pH 6.0 and immobilized on a BIAcore CM5 sensor chip (research
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grade, GE Healthcare, Piscataway, NJ) with the amine coupling kit
according to the manufacturer’s instructions. About 1500 resonance units
were coupled to the chip for analysis in a BIAcore 3000 instrument (GE
Healthcare, Piscataway, NJ). The kinetic analysis was performed at 25°C in
10 mM HEPES buffer, pH 7.4 including 150 mM NaCl, 2 mM CaCl2 and
0.005% (v/v) surfactant P20 (running buffer) at a flow rate of 20 μl/min.
Purified recombinant fibrillin-1 and -2 fragments, as described previously
(Jensen et al., 2001; Lin et al., 2002), were diluted in running buffer at
different concentrations and injected through an uncoupled control flow cell
and the flow cell coupled to ADAMTSL2 (Koo et al., 2007). Association
was allowed for 3-6 min followed by a 10-min dissociation phase. 1 MNaCl
with 2–10% (v/v) acetonitrile was used for regeneration after each injection
at a flow rate of 50 μl/min for 30‐60 s. The stabilization time following the
regeneration was 2 min.
TGFβ neutralizing antibody treatment
Adamtsl2+/− dams from timed pregnancies after crosses to Adamtsl2+/−
males were injected intraperitoneally at E13.5 and E17.5 with the pan-
TGFβ-neutralizing antibody 1D11 or an isotype matched IgG control
(10 mg/kg body weight in PBS), both purchased from R&D Systems
(Minneapolis, MN). Lung tissue was harvested at P0 and processed for
histology as described above. Intraperitoneal injection of this antibody is
commonly used to neutralize active TGFβ in mouse tissue in vivo (Neptune
et al., 2003; Nakanishi et al., 2007). Moreover, it has been shown that
specifically the IgG1 antibodies subtype, to which the TGFβ 1D11 antibody
belongs, can cross the placental barrier (Paoletti et al., 2000; Pentsuk and
van der Laan, 2009; Qi et al., 2012).
Acknowledgements
We thankDr SarahDallas (University of Missouri, Kansas City,MO) for the generous
gift of the LTBP1 antibody. We thank Brittany Matuska for assisting with tissue
sectioning and genotyping. SPR experiments were performed in the Molecular
Biotechnology Core of the Lerner Research Institute. We thank the histology core of
the Department of Biomedical Engineering for tissue processing and Mei Win
(Imaging Core of the Lerner Research Institute) for help with transmission electron
microscopy.
Competing interests
The authors declare no competing or financial interests.
Author contributions
D.H. and S.S.A. conceived and designed the experiments. D.H. and L.W.W.
performed the experiments. D.H., L.W.W., R.P.M., D.P.R. and S.S.A. analyzed the
data. R.P.M. and D.P.R. contributed reagents. D.H. and S.S.A. wrote the paper.
Funding
This work was supported by awards from the Marfan Foundation [Early Investigator
Grant Program to D.H.]; the National Institutes of Health [AR53890, EY02511 to S.S.
A. and HL53325, HL74138 to R.P.M.]; and the Canadian Institutes of Health
Research [MOP-106494 to D.P.R.].
Supplementary material
Supplementary material available online at
http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.017046/-/DC1
References
Allali, S., Le Goff, C., Pressac-Diebold, I., Pfennig, G., Mahaut, C., Dagoneau, N.,
Alanay, Y., Brady, A. F., Crow, Y. J., Devriendt, K. et al. (2011). Molecular
screening of ADAMTSL2 gene in 33 patients reveals the genetic heterogeneity of
geleophysic dysplasia. J. Med. Genet. 48, 417-421.
Arteaga-Solis, E., Gayraud, B., Lee, S. Y., Shum, L., Sakai, L. and Ramirez, F.
(2001). Regulation of limb patterning by extracellular microfibrils. J. Cell Biol. 154,
275-282.
Bader, H. L., Ruhe, A. L., Wang, L. W., Wong, A. K., Walsh, K. F., Packer, R. A.,
Mitelman, J., Robertson, K. R., O’Brien, D. P., Broman, K. W. et al. (2010). An
ADAMTSL2 founder mutation causes Musladin-Lueke Syndrome, a heritable
disorder of beagle dogs, featuring stiff skin and joint contractures. PLoS ONE 5,
e12817.
Baldwin, A. K., Cain, S. A., Lennon, R., Godwin, A., Merry, C. L. R. and Kielty,
C. M. (2014). Epithelial-mesenchymal status influences how cells deposit fibrillin
microfibrils. J. Cell Sci. 127, 158-171.
Beene, L. C., Wang, L. W., Hubmacher, D., Keene, D. R., Reinhardt, D. P., Annis,
D. S., Mosher, D. F., Mecham, R. P., Traboulsi, E. I. and Apte, S. S. (2013).
Nonselective assembly of fibrillin 1 and fibrillin 2 in the rodent ocular zonule and in
cultured cells: implications for marfan syndrome. Invest. Ophthalmol. Vis. Sci. 54,
8337-8344.
Brooke, B. S., Habashi, J. P., Judge, D. P., Patel, N., Loeys, B. andDietz, H. C., III
(2008). Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome.
N. Engl. J. Med. 358, 2787-2795.
Carta, L., Pereira, L., Arteaga-Solis, E., Lee-Arteaga, S. Y., Lenart, B., Starcher,
B., Merkel, C. A., Sukoyan, M., Kerkis, A., Hazeki, N. et al. (2006). Fibrillins 1
and 2 perform partially overlapping functions during aortic development. J. Biol.
Chem. 281, 8016-8023.
Chen, Q., Sivakumar, P., Barley, C., Peters, D. M., Gomes, R. R., Farach-Carson,
M. C. and Dallas, S. L. (2007). Potential role for heparan sulfate proteoglycans in
regulation of transforming growth factor-beta (TGF-beta) by modulating assembly
of latent TGF-beta-binding protein-1. J. Biol. Chem. 282, 26418-26430.
Cohn, R. D., van Erp, C., Habashi, J. P., Soleimani, A. A., Klein, E. C., Lisi, M. T.,
Gamradt, M., ap Rhys, C. M., Holm, T. M., Loeys, B. L. et al. (2007). Angiotensin
II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle
regeneration in multiple myopathic states. Nat. Med. 13, 204-210.
Cook, J. R., Carta, L., Benard, L., Chemaly, E. R., Chiu, E., Rao, S. K., Hampton,
T. G., Yurchenco, P., Gen, T. A. C. R. C., Costa, K. D. et al. (2014). Abnormal
muscle mechanosignaling triggers cardiomyopathy in mice with Marfan
syndrome. J. Clin. Invest. 124, 1329-1339.
Corson, G. M., Charbonneau, N. L., Keene, D. R. and Sakai, L. Y. (2004).
Differential expression of fibrillin-3 adds to microfibril variety in human and avian,
but not rodent, connective tissues. Genomics 83, 461-472.
Doyle, J. J., Gerber, E. E. andDietz, H. C. (2012). Matrix-dependent perturbation of
TGFbeta signaling and disease. FEBS Lett. 586, 2003-2015.
Gabriel, L. A. R., Wang, L.W., Bader, H., Ho, J. C., Majors, A. K., Hollyfield, J. G.,
Traboulsi, E. I. and Apte, S. S. (2012). ADAMTSL4, a secreted glycoprotein
widely distributed in the eye, binds fibrillin-1 microfibrils and accelerates microfibril
biogenesis. Invest. Ophthalmol. Vis. Sci. 53, 461-469.
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